Evidence map›Paper›PMID 31590648›Full record

ArticleBMC infectious diseases2019

Risk factors and survival of patients infected with carbapenem-resistant Klebsiella pneumoniae in a KPC endemic setting: a case-control and cohort study.

Astrid V Cienfuegos-Gallet, Ana M Ocampo de Los Ríos, Patricia Sierra Viana, Faiver Ramirez Brinez, Carlos Restrepo Castro, Gustavo Roncancio Villamil, Helena Del Corral Londoño, J Natalia Jiménez

Open access · goldAbstract read
In one paragraph

Article in BMC infectious diseases, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 31 papers, 4 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
31citing papers in PubMed, 4 pooled it
2.4field-weighted citation impact, top 10% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

31 citing papers in PubMed, 4 syntheses or guidelines pooled it, 54 citations in OpenAlex.

  1. Pooled it
  2. Risk factors for carbapenem-resistantFrontiers in public health · 2026
    Pooled it
  3. Pooled it
  4. Pooled it
  5. Observational
  6. Article
  7. Clinical Epidemiological Analysis of the Genotypic Spectrum and Mortality Risk in Carbapenem-ResistantThe Canadian journal of infectious diseases & medical microbiology = Journal canadien des maladies infectieuses et de la microbiologie medicale · 2026
    Review
  8. Clinical and genomic characterization ofFrontiers in microbiology · 2025
    Article
  9. Article
  10. Enhanced invasion and survival of antibiotic- resistantFrontiers in cellular and infection microbiology · 2025
    Article
  11. Observational
  12. Article
  13. Article
  14. Article
  15. Review
  16. Analysis of risk factors associated with healthcare-associated carbapenem-resistant Klebsiella pneumoniae infection in a large general hospital: a case-case-control study.European journal of clinical microbiology & infectious diseases : official publication of the European Society of Clinical Microbiology · 2023
    Article
  17. Article
  18. Article
  19. Article
  20. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors at 2 institutions in 1 country.

Astrid V Cienfuegos-GalletLínea de Epidemiología Molecular Bacteriana, Grupo de Microbiología Básica y Aplicada, Escuela de Microbiología, Universidad de Antioquia, 050010, Medellín, Colombia. astrid.cienfuegos@udea.edu.co.ORCID http://orcid.org/0000-0002-3407-6463
Ana M Ocampo de Los RíosLínea de Epidemiología Molecular Bacteriana, Grupo de Microbiología Básica y Aplicada, Escuela de Microbiología, Universidad de Antioquia, 050010, Medellín, Colombia.
Patricia Sierra VianaIPS Universitaria Clínica León XIII, 050010, Medellín, Colombia.
Faiver Ramirez BrinezIPS Universitaria Clínica León XIII, 050010, Medellín, Colombia.
Carlos Restrepo CastroIPS Universitaria Clínica León XIII, 050010, Medellín, Colombia.
Gustavo Roncancio VillamilLínea de Epidemiología Molecular Bacteriana, Grupo de Microbiología Básica y Aplicada, Escuela de Microbiología, Universidad de Antioquia, 050010, Medellín, Colombia.
Helena Del Corral LondoñoLínea de Epidemiología Molecular Bacteriana, Grupo de Microbiología Básica y Aplicada, Escuela de Microbiología, Universidad de Antioquia, 050010, Medellín, Colombia.
J Natalia JiménezLínea de Epidemiología Molecular Bacteriana, Grupo de Microbiología Básica y Aplicada, Escuela de Microbiología, Universidad de Antioquia, 050010, Medellín, Colombia. jnatalia.jimenez@udea.edu.co.
Universidad de Antioquia · COClínica Somer · CO

Funding

Departamento Administrativo de Ciencia, Tecnología e Innovación 111565741641
6 · The paper itself

Abstract

backgroundMany gaps in the burden of resistant pathogens exist in endemic areas of low- and middle-income economies, especially those endemic for carbapenem resistance. The aim of this study is to evaluate risk factors for carbapenem-resistance, to estimate the association between carbapenem-resistance and all-cause 30-day mortality and to examine whether mortality is mediated by inappropriate therapy.

methodsA case-control and a cohort study were conducted in one tertiary-care hospital in Medellín, Colombia from 2014 to 2015. Phenotypic and genotypic characterization of isolates was performed. In the case-control study, cases were defined as patients infected with carbapenem-resistant K. pneumoniae (CRKP) and controls as patients infected with carbapenem-susceptible K. pneumoniae (CSKP). A risk factor analysis was conducted using logistic regression models. In the cohort study, the exposed group was defined as patients infected with CRKP and the non-exposed group as patients infected with CSKP. A survival analysis using an accelerated failure time model with a lognormal distribution was performed to estimate the association between carbapenem resistance and all-cause 30-day-mortality and to examine whether mortality is mediated by inappropriate therapy.

resultsA total of 338 patients were enrolled; 49 were infected with CRKP and 289 with CSKP. Among CRKP isolates CG258 (n = 29), ST25 (n = 5) and ST307 (n = 4) were detected. Of importance, every day of meropenem (OR 1.18, 95%CI 1.10-1.28) and cefepime (OR 1.22, 95%CI 1.03-1.49) use increase the risk of carbapenem resistance. Additional risk factors were previous use of ciprofloxacin (OR 2.37, 95%CI 1.00-5.35) and urinary catheter (OR 2.60, 95%CI 1.25-5.37). Furthermore, a significant lower survival time was estimated for patients infected with CRKP compared to CSKP (Relative Times 0.44, 95%CI 0.24-0.82). The strength of association was reduced when appropriate therapy was included in the model (RT = 0.81 95%CI 0.48-1.37).

conclusionShort antibiotic courses had the potential to reduce the selection and transmission of CRKP. A high burden in mortality occurred in patients infected with CRKP in a KPC endemic setting and CRKP leads to increased mortality via inappropriate antibiotic treatment. Furthermore, dissemination of recognized hypervirulent clones could add to the list of challenges for antibiotic resistance control.

Indexed as

Carbapenem-Resistant EnterobacteriaceaeEndemic DiseasesAgedAnti-Bacterial AgentsCase-Control StudiesCefepimeCiprofloxacinColombiaDrug Resistance, Multiple, BacterialFemaleGenotypeHumansKaplan-Meier EstimateKlebsiella InfectionsKlebsiella pneumoniaeLogistic ModelsAnti-Bacterial AgentsCefepimeCiprofloxacinMeropenemCarbapenem resistanceCase-control studyCohort studyinnapropriate therapyKlebsiella pneumoniaelength of antibiotic usemortalityrisk factors

Identifiers

PMID31590648
PMCPMC6781339
OpenAlexW2978758971

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.